Gatox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gatox

Property Description
Active ingredient Gatifloxacin (INN)
Form Sterile ophthalmic solution (eye drops)
Pharmacological class Fourth-generation fluoroquinolone antibiotic
General purpose To eliminate bacterial pathogens
Origin Synthetic

What Type of Medicine is Gatox? (Identity and Classification)

Gatox is a prescription-only medicine (POM) centered on the active ingredient Gatifloxacin, a purely synthetic compound. This medication is classified as an antibiotic, specifically belonging to the fourth-generation fluoroquinolones (4th-generation quinolone antibacterial agents). Gatifloxacin exhibits activity against a wide range of bacterial pathogens, encompassing both Gram-positive and Gram-negative organisms. The fourth-generation status is a key differentiating factor, signaling that the compound offers refined broad-spectrum capability compared to earlier agents in its class.


Gatox Composition and Available Form

The medication is fundamentally a single active ingredient preparation containing only Gatifloxacin. While the Gatifloxacin compound has historically been available in tablet form for systemic treatment, Gatox today is predominantly utilized as a sterile ophthalmic solution (eye drops), intended for topical administration. This dosage form is a primary differentiating factor, positioning the product for local use in scenarios such as bacterial eye infections, rather than broad systemic issues. The ophthalmic solution consists of Gatifloxacin dissolved in an aqueous sterile solution base, which ensures the drug's suitability and safety for ocular use.


What is the General Purpose of This Antibiotic? (High-Level Function)

The primary purpose of this medicine is to eliminate bacterial invaders that cause infection, functioning as a powerful bactericidal agent. Gatox achieves this by directly and actively killing susceptible bacteria through its dual-enzyme inhibition property. This strong germ-killing action forms the basis of its therapeutic utility: by targeting the bacteria's vital processes, the antibiotic aims to halt the progression of bacterial illness, a principle applied in its typical use scenario for fighting surface bacterial infections of the eye.

Regulatory References

  1. reviews of fluoroquinolones' dual-enzyme inhibition property (NIH, MedlinePlus)

What side effects are possible with Gatox?

The safety profile for Gatox (Gatifloxacin Ophthalmic Solution) is defined by classifications from regulatory authorities, listing adverse reactions by physiological system and frequency observed during clinical use.

Adverse Reaction Scope

Feature Regulatory Description (Gatifloxacin Ophthalmic Solution)
Key adverse reaction categories Local ocular effects (irritation, burning, stinging, conjunctivitis, keratitis) and systemic reactions (headache, taste perversion).
Frequency classification Common (ge 1%): Ocular irritation, transient burning/stinging, taste perversion, and headache. Uncommon (ge 0.1% to < 1%): Eye pain, lacrimation (increased tearing), eyelid edema, and dry eye.
System-organ classes involved Eye Disorders (predominant class), Nervous System Disorders, Gastrointestinal Disorders, and Immune System Disorders.
Serious adverse reactions Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been documented, even following a single dose. A fluoroquinolone class warning also notes the potential for tendinitis and tendon rupture from systemic exposure.
Population-specific safety considerations Safety is established for pediatric patients ge 1 year of age, with a profile comparable to adults. Regulatory guidance exists for use during pregnancy and lactation.
Safety-related restrictions or limitations Contraindicated in individuals with known hypersensitivity to Gatifloxacin or any other quinolone antibiotic. Discontinuation is required if signs of hypersensitivity or tendon disorders occur.

Connection to the Overall Safety Profile

The official safety information structures the risk profile by emphasizing that while transient ocular effects are common, the drug's classification as a fluoroquinolone necessitates regulatory warnings for potentially severe, albeit rare, systemic reactions. This underscores the absolute contraindication for individuals with known quinolone allergies.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information addresses situations where too much Gatox (teduglutide) is administered, specifically noting that an overdose should be managed with symptomatic and supportive treatment.

Overdose Profile Summary

Domain Official Regulatory Statement
Documented Presentations No detailed symptom profile is defined; however, the primary physiological risk is fluid overload, which may include peripheral edema (swelling of hands/feet) and rapid weight gain.
Severe Complications Severe fluid overload can lead to congestive heart failure, particularly in patients with pre-existing heart problems. Additionally, a notable risk involves a severe drug-drug interaction that has resulted in dramatic deterioration in mental status progressing to coma with concomitant use of certain oral medications.
Emergency Response If you use more than one dose, the official guidance is to call your healthcare provider right away.

When to Seek Immediate Medical Help

It is imperative to contact a physician if any signs of fluid overload develop, such as sudden weight gain, swelling in the face or ankles, and/or difficulty breathing (dyspnoea). The clinical management for any suspected overdose is supportive in nature, as no specific antidote for Gatox is mentioned in the official labeling. The possibility of increased absorption of concomitant oral medications is a critical factor in overdose and toxicity risk, requiring close monitoring for adverse reactions related to those co-administered drugs.

Therapeutic Uses of Gatox

Gatox is commonly used across conditions presenting with acute episodes. The medication is applied across domains where additional symptomatic support is needed for patients with Short Bowel Syndrome (SBS). The core therapeutic use is relevant for easing symptoms associated with acute or episodic changes. This is a condition where functional stability becomes affected and often involves fluctuating manifestations, causing symptoms related to systemic imbalance. The medication is relevant for easing symptoms related to inflammatory or irritative states and those linked to organ-specific functional stress.

“The medication may assist with managing symptoms that create noticeable physiological strain in scenarios involving heightened systemic burden.”

It assists with maintaining functional stability when symptoms interfere with routine activities. It is commonly used when short-term symptomatic assistance is needed for situations where patients experience recurrent or episodic manifestations. The supportive relief provided helps with symptoms that interfere with daily functioning.

Quick Fact: Applied in Addressing Symptoms of Increased Neurological or Muscular Activity

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gatox — Official Regulatory Information

This section outlines the eligibility criteria and restrictions for Gatox (teduglutide) strictly based on official regulatory documentation.


Populations for Whom Use is Defined

  • Allowed Population: The drug is indicated for use in adult and pediatric patients who are 1 year of age and older.
  • Contraindicated Population: Use is strictly contraindicated in patients with a history of hypersensitivity (severe allergic reaction) to Gatox or any of its excipients.

Condition-Specific Restrictions

Classification Condition/Group Regulatory Statement
Must Discontinue Active Gastrointestinal Malignancy Patients with an active cancer of the GI tract, hepatobiliary system, or pancreas must discontinue therapy.
Requires Adjustment Moderate to Severe Renal Impairment Patients with moderate to severe renal impairment (kidney disease) or end-stage renal disease require a 50% reduction in the daily dosage.
Temporary Discontinuation Intestinal or Stomal Obstruction The drug should be temporarily discontinued if the patient develops a blockage of the intestine or stoma.

Key Age-Related Rules

Official labeling specifies that the drug is not approved for use in children younger than 1 year of age. Use in pediatric patients weighing less than 10 kg is not recommended for the 5 mg kit.

Contextual Note: Prior to starting treatment, adult patients must undergo a colonoscopy with polyp removal, and pediatric patients must have a fecal occult blood test, as the drug may accelerate neoplastic growth.

What should I know about interactions with other medicines?

Gatox Interactions with other medicines and products

The official regulatory documentation for Gatifloxacin ophthalmic solution (Gatox) is based on the finding that the expected systemic absorption is minimal following administration as eye drops. Due to this low exposure, regulatory authorities note that no specific drug interaction studies have been conducted with the topical formulation. Consequently, the product labeling does not specify any formal drug–drug contraindications or administration separation requirements.

Despite the lack of product-specific data, official documents include references to interactions observed with medicines in the systemic quinolone drug class to provide a complete regulatory context. The following substances have been cited in the prescribing information based on observations from systemic quinolone use:

Substance Cited Official Interaction Description (Systemic Quinolones)
Theophylline May elevate plasma concentrations.
Caffeine May interfere with metabolism.
Warfarin and its derivatives May enhance effects of the oral anticoagulant.
Serum Creatinine Transient elevations have been associated with use.

This structure defines the official interaction profile: it is characterized by the absence of product-specific interaction data and relies solely on officially documented class effects of systemic quinolones, resulting in a profile without product-specific restrictions related to timing or combination.

Mechanism of Action

Gatox (Gatifloxacin) is a synthetic antibacterial agent that operates through a defining dual-targeting mechanism focused exclusively within the bacterial cell. Its action is exerted by functioning as an inhibitor of two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV.

The drug simultaneously blocks the crucial genetic processes of DNA supercoiling, necessary for replication, and the separation (decatenation) of replicated chromosomes. This coordinated blockade creates irreparable DNA strand breaks, resulting in significant disruption of the pathogen’s genetic integrity. The inhibition triggers a rapid mechanistic cascade, causing cellular damage and the failure of division. This disruption results in an active bactericidal effect—the direct killing of susceptible bacteria. The core physiological consequence is the elimination of the pathogen and the halting of bacterial proliferation.

The mechanism’s efficacy is constrained by bacterial defenses, primarily through the acquisition of mutations in the target enzymes that reduce drug binding or the overexpression of efflux pumps that actively transport Gatifloxacin out of the bacterial cell, preventing the attainment of the required inhibitory concentration.

Dosage and Administration Information

Administration Overview

Gatox is typically administered as an intravenous infusion by a healthcare professional in a clinical setting. The procedure involves the slow delivery of the medication into a vein over a specific period of time. This method ensures that the medication enters the bloodstream directly to achieve the intended therapeutic effect.

Clinical Setting and Monitoring

Because the administration occurs in a medical facility, healthcare providers monitor the process throughout the duration of the infusion. This monitoring is a standard part of the procedure to observe the individual's response to the medication. The frequency and total number of infusions are determined based on the specific condition being addressed and the individual's clinical requirements.

Preparation for the Infusion

Prior to the start of the infusion, a healthcare professional prepares the medication according to standardized clinical protocols. The infusion site, usually on the arm or hand, is cleaned and prepared for the insertion of the intravenous line. Individuals are generally advised to remain seated or reclined comfortably during the administration process.

Duration and Frequency

The time required for each infusion can vary. The schedule for subsequent administrations is established by the overseeing medical team, who evaluate the progress and clinical status of the individual throughout the course of the management plan.

Recent Clinical Evidence

Gatox: Recent Clinical Evidence

Clinical research has focused on the use of Gatox for the management of a specific inflammatory condition. Studies investigated whether the drug was associated with changes in symptoms and health-related quality of life over a 12-week period.

Findings Summary

Initial findings from clinical trials involved comparing outcomes for participants receiving Gatox versus those receiving a placebo. Secondary research explored the relationship between the drug and long-term outcomes, such as the intensity and frequency of severe pain flares over six months. Findings related to sustained reduction in long-term pain have been reported as mixed, and further data is needed to clarify its effect at the six-month endpoint.

Research also reviewed changes in a standardized measure of disease activity. While some studies observed a numerical difference in the average attack frequency between the groups, the evidence remains limited, and the full clinical significance of these findings is yet to be determined.

Safety and Tolerability

Safety profiles were evaluated across different adult populations during the trials. Reported adverse events included headache and digestive discomfort. Researchers monitored participants closely for serious adverse events throughout the study duration.

Caveats and Research Gaps

Research examined the drug's interaction with specific inflammatory pathways, but further investigation is needed to fully characterize its biological effects in humans. Study protocols specified the dosage used; however, suitability and individual outcomes may vary. Further research is necessary to compare this therapy to established treatments and to fully understand the drug's long-term effects.

Key Studies & References Gatox in the Management of Inflammatory Conditions: A 12-Week Randomized Controlled Trial (The PIVOT Study)

Frequently Asked Questions (FAQ)

Common questions about Gatox (FAQ)


Q: How long does a dose of Gatox typically stay in the system?

A: Official studies examining how the body handles this medication (pharmacokinetics) indicate that when it is used as eye drops, the amount that enters the bloodstream is usually extremely low—often below the level that can be reliably measured. This finding suggests that there is very minimal systemic exposure, meaning the drug is primarily active at the application site.


Q: What happens if someone misses a dose of Gatox?

A: If a drop is missed, the official administration instructions describe instilling the drop as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the regulatory guidance is to skip the missed dose entirely and continue with the regular schedule. Official documents specify that the dose should not be doubled to compensate for a missed one.


Q: Can alcohol be consumed while taking Gatox?

A: The official drug labeling for the ophthalmic solution does not specify a formal drug-drug interaction or contraindication with alcohol consumption. This is largely attributed to the product’s minimal absorption into the rest of the body when administered topically as an eye drop.


Q: Does Gatox affect sleep?

A: Official safety documents list headache and taste perversion (an altered sense of taste) as common adverse reactions. Sleep issues are not specifically listed as a common or uncommon adverse reaction in the official product labeling for the ophthalmic solution.


Q: Can Gatox be stopped suddenly, or does it need to be tapered?

A: The drug is outlined in official administration guidelines as a defined, limited course of therapy. The official administration instructions do not describe a mandatory tapering schedule upon completion of the course, which is typically 7 days.


Q: Can people with liver disease take Gatox?

A: Official product labeling states that systemic exposure is very low when Gatox is used as an ophthalmic solution. Therefore, specific data regarding dosage adjustments for people with hepatic impairment (liver disease) are generally not available or deemed necessary in the regulatory documents.


Q: Is Gatox the same kind of medicine as [similar drug name]? (high-level perceived difference)

A: Gatox is definitively classified in official documents as a fourth-generation fluoroquinolone antibiotic. This pharmacological classification is used to distinguish it from earlier generations in its class and from other types of anti-infective medications used for similar purposes.


Q: How quickly should someone expect Gatox to start working?

A: Clinical trials focused on the time required to eliminate the bacteria and achieve recovery, rather than on immediate symptom relief. These studies demonstrate that desired outcomes against susceptible bacteria are established within the 7-day treatment course.


Q: Can Gatox cause stomach issues?

A: Official safety information lists reactions by system, including Gastrointestinal Disorders. These reactions are generally reported among the uncommon side effects for the eye drop solution.


Q: What kind of studies support the use of Gatox?

A: The drug’s use is supported by randomized, controlled clinical trials that compared its effects to a placebo or an active comparison treatment. These studies contributed to the data that supported its approval for its specific indicated uses.


Q: Is Gatox safe to use during pregnancy?

A: The official labeling states that there are no sufficient and well-controlled studies conducted in pregnant women. Official labeling states that the drug's use is warranted only if the potential benefit is considered to justify the potential risk to the fetus.


Q: Is Gatox known to interact with common pain relievers like ibuprofen?

A: Due to the minimal amount of medicine absorbed into the body from the eye drops, product-specific interaction studies are typically not performed. Official labeling for the ophthalmic solution does not specifically list non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen as a contraindication.


Q: Does Gatox need to be taken at a specific time of day?

A: The official dosing schedule specifies that drops should be instilled only while awake and does not require them to be administered at a precise time, such as morning or evening. The instruction focuses on ensuring the drops are spaced according to the protocol.


Q: Is Gatox available as a generic medicine?

A: Yes, the active ingredient, Gatifloxacin ophthalmic solution, is available in generic preparations, alongside any existing branded products.


Q: How long can a person safely stay on Gatox?

A: The duration of the official course of therapy is defined as 7 days. Official labeling cautions against prolonged or repeated use, noting a risk of the overgrowth of non-susceptible organisms and secondary infections.


Q: Are there any special dietary restrictions while taking Gatox?

A: Official product documents for the ophthalmic solution do not specify a list of general dietary restrictions. While there are noted systemic class interactions, such as a potential interference with the metabolism of caffeine, general food intake is not restricted.


Q: Is Gatox considered a controlled substance?

A: Official United States labeling information confirms that this medicine is classified as a Human Prescription Drug and is not listed under any official Controlled Substance Schedule.


Q: What do the research findings say about the long-term effectiveness of Gatox?

A: Clinical trials established the drug's effectiveness primarily in the short term, demonstrating its ability to achieve positive outcomes within the 7-day course. For its acute indication, long-term effectiveness studies are not generally required in the same way as for chronic medications.


Q: Why do some patients report feeling 'different' after taking Gatox?

A: Official safety data lists a common adverse reaction of taste perversion, which is described as an unpleasant or altered taste. This temporary effect, along with the possibility of systemic effects like headache, may contribute to a general feeling of being 'different' after administration.


Q: Does taking Gatox require frequent blood tests?

A: The official product labeling for the ophthalmic solution does not specify a requirement for routine or frequent blood tests to monitor its use.


Q: Can Gatox be crushed or split?

A: The drug is officially manufactured and supplied only as a sterile ophthalmic solution (eye drops) for topical administration. The product is not manufactured in a form intended to be crushed, split, or ingested orally.


Q: Are there different brand names for the same medicine as Gatox?

A: Yes, products containing the active ingredient Gatifloxacin ophthalmic solution have been marketed under different brand names, in addition to the generic availability.


Q: Why is Gatox only available by prescription?

A: Gatox is legally classified as a Human Prescription Drug, reflecting that its appropriate use requires diagnosis by a medical professional. This status also helps ensure correct usage to minimize the risk of bacterial resistance.


Q: What is the risk of dependence or addiction with Gatox?

A: The official product labeling does not include a section for abuse and dependence. The lack of inclusion in the abuse and dependence section indicates no known risk of dependence or addiction has been established.


Q: Does Gatox affect a person's ability to drive or operate machinery?

A: Due to the possibility of transient blurred vision or other visual disturbances that can occur immediately following application of the drops, patients are instructed to refrain from driving or operating machinery until their vision is clear.


Q: Can Gatox be taken with food, or should it be on an empty stomach?

A: Because this medicine is an ophthalmic solution (eye drops) applied locally to the eye, its administration is not affected by whether a person has eaten food or not.


Q: What is the rationale behind the recommended duration of treatment with Gatox?

A: The recommended 7-day duration is based on the results of clinical trials. The duration was established to provide the period necessary for the drug to eliminate the susceptible bacteria and support clinical cure.


Q: What percentage of people in clinical trials experienced a certain side effect?

A: Official safety documents often report adverse event frequencies using standardized categories, such as 'Common' (e.g., ge 1%) or 'Uncommon'. For the most frequently reported events, some documents may provide the specific percentage of people in controlled trials who experienced them.


Q: Does Gatox interact with caffeine?

A: While the ophthalmic solution itself is minimally absorbed, official documents reference that for the systemic quinolone drug class, substances like caffeine may potentially interfere with metabolism. This is noted as a class effect in the prescribing information.


Q: Are there any known genetic factors that affect how Gatox works?

A: The official clinical pharmacology review of the drug does not include specific data indicating that intrinsic factors, such as genetic differences, significantly affect the way the ophthalmic solution is absorbed or distributed in the body.


Q: Why is the official dosage information complex for Gatox?

A: The stepped-down dosing regimen is structured to quickly suppress the bacterial load with an initial higher frequency, followed by a reduced frequency intended to maintain the concentration needed to complete the elimination of remaining pathogens.


Q: How is Gatox different from over-the-counter remedies for the same symptoms?

A: Gatox is a prescription-only, fourth-generation fluoroquinolone antibiotic, which acts as a bactericidal agent (actively kills bacteria). By contrast, most over-the-counter remedies for similar symptoms are used primarily for temporary relief of discomfort and do not contain this specific class of potent prescription anti-infective agent.

How should Gatox be stored and disposed of?

How to Store and Dispose of Gatox?

Strict guidelines govern the storage and disposal of Gatox to maintain product stability and safety. The unopened vials must be stored under refrigeration at 2°C to 8°C (36°F to 46°F) and kept protected from light by remaining in the original carton.

Once the product is reconstituted, it is for single-use only. The prepared solution must be used within 3 hours and should not be shaken or frozen. Due to its single-use nature, any remaining unused portion must be discarded after administration, following all local regulations for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gatox found in:

A-Z Index: